Skip to Content

Call 1-833-ELAHERE1-833-ELAHERE for the ELAHERE Support Services Program

ORDER ELAHERE

Call 1-833-ELAHERE1-833-ELAHERE for the ELAHERE Support Services Program

ORDER ELAHERE

SUPPORT FOR YOUR PATIENTS

Enroll in ELAHERE Support Services

ELAHERE Support Services: Here to help your patients navigate access to their treatment

ELAHERE Support Services (ESS) is committed to helping appropriate patients start on ELAHERE by offering access and reimbursement support, affordability assistance, and dedicated nursing support for patient questions based on the Prescribing Information.

ELAHERE® Support Services

What ESS offers

Once enrolled, ESS offers the following services and programs for patients:

Reimbursement Icon

Access & reimbursement

  • Benefits investigation
  • Prior authorization assistance
  • Appeals assistance
Copay Icon

Co-pay assistance*

  • Support for commercially eligible patients with out-of-pocket costs
  • Patients could pay as little as $0 for their medication
Patient Assistance Icon

Patient assistance

  • Support for uninsured or underinsured patients who meet eligibility requirements to access medication at no charge†
Nurse navigators

Nurse Navigators

  • A resource available to patients and their caregivers to answer questions about their treatment based on the Prescribing Information

Get in touch with ELAHERE Support Services

For questions, connect with an ELAHERE Support Services Program specialist by calling 1-833-ELAHERE (1-833-352-4373) Monday to Friday, 8 AM to 8 PM ET or emailing ELAHERESupport@cardinalhealth.com

Call ELAHERE Support Services

1-833-ELAHERE (1-833-352-4373)

1-833-464-6329

Patient Website
Email ELAHERE Support Services

ELAHERESupport@cardinalhealth.com

Download ELAHERE Support Services Patient Enrollment Form

Order ELAHERE

To order ELAHERE, contact your participating specialty distributor or specialty pharmacy listed in the ELAHERE Ordering Information Sheet.

Download the ELAHERE Ordering Information Sheet

J-Code for ELAHERE

Effective July 1, 2023, the permanent J-Code for ELAHERE is J9063 - Injection, mirvetuximab soravtansine-gynx, 1 mg.‡

The Centers for Medicare & Medicaid Services (CMS) released the April 2023 Quarterly Healthcare Common Procedural Coding System (HCPCS) file, which includes the designation of J9063 for injection, mirvetuximab soravtansine-gynx, 100 mg/20 mL.

Test for FRα

More than a dozen central labs are validated for FOLR1 IHC testing. Check with your preferred lab directly for availability

Contact your ELAHERE representative for updated information about testing for FRα

Resources for your practice

ELAHERE HCP Brochure

ELAHERE Overview Brochure

Clinical information about ELAHERE

Download Brochure
ELAHERE Dosing and Administration Booklet

Dosing and Administration Booklet

Information about how ELAHERE infusions are dosed and administered

Download Booklet
ELAHERE Ocular Assessment Form

Ocular Assessment Form

Offer your patients a checklist to track any ocular events they may experience

Download Form
Elahere Ordering Information Sheet

ELAHERE Ordering Information Sheet

Information on how to order ELAHERE through specialty distributors or specialty pharmacy partners

Download SHEET
ELAHERE Support Services Enrollment Form

ELAHERE Support Services Patient Enrollment Form

Enroll your patients in the ELAHERE Support Services program to receive access, reimbursement, and affordability support

Download Form
Spanish ELAHERE Support Services Enrollment Form

Spanish ELAHERE Support Services Patient Enrollment Form

Enroll your patients in the ELAHERE Support Services program to receive access, reimbursement, and affordability support

Download Form
ELAHERE Billing and Coding Guide

ELAHERE Billing and Coding Guide

Physician office and hospital/outpatient coding information to reference when billing and submitting claims for ELAHERE

Download Guide
Ocular Billing and Coding Guide

Ocular Billing and Coding Guide

Ophthalmic exam codes for eye care providers to reference when billing and submitting claims

Download Guide
Cerner EHR Query Instructions

Cerner EHR Query Instructions

Considerations for identifying appropriate patients for FRα testing and mirvetuximab soravtansine-gynx treatment evaluation in the Cerner EHR system

Download
Epic EHR Query Instructions

Epic EHR Query Instructions

Considerations for identifying appropriate patients for FRα testing and mirvetuximab soravtansine-gynx treatment evaluation in the Epic EHR system

Download
Epic FRα Testing Alert

Epic FRα Testing Alert

A support tool to help create a Best Practice Advisory to identify patients with ovarian cancer who may be candidates for FRα testing in the Epic EHR system

Download
Cerner FRα Testing Alert

Cerner FRα Testing Alert

A support tool to help create a discern alert to identify patients with ovarian cancer who may be candidates for FRα testing in the Oracle Cerner EHR system

Download
Epic AIBW Calculator + Order Set Instructions

Epic AIBW Calculator + Order Set Instructions

Instructions to optimize order sets and integrate an AIBW calculator into the Epic EHR system

Download

Resources for your patients

Medication Guide

Medication Guide

Important information about ELAHERE treatment

Download Guide

Spanish-language patient resources

Spanish Medication Guide

Spanish Medication Guide

Important information about ELAHERE treatment

Download Guide

Helpful videos

Learn about ELAHERE from experts

Hear fellow healthcare professionals talk about various topics relevant to platinum-resistant ovarian cancer (PROC) and treatment with ELAHERE.

ELAHERE HCP Brochure

Platinum Resistance in Ovarian Cancer

Watch gynecologic oncologist Dr Kristin Taylor discuss perspectives on platinum-resistant ovarian cancer, how it affects treatment, and ELAHERE as an option

ELAHERE Dosing and Administration Booklet

How an ADC Works in Platinum- Resistant Ovarian Cancer

Watch gynecologic oncologist Dr Kristin Taylor discuss what antibody-drug conjugates (ADCs) are, how they can provide targeted treatment in PROC, and how ELAHERE works

Eye care videos

Learn more about eye care for patients receiving ELAHERE, from how to effectively work with their care team to helping them understand what they can expect while on treatment.

ELAHERE HCP Brochure

Eye Care Provider Best Practices

See an overview of ELAHERE treatment and the important role eye care providers play in helping to proactively manage ocular events, as well as best practices and available resources

ELAHERE Dosing and Administration Booklet

What Patients Can Expect at Eye Care Exams

Watch Dr Kristen Lamoreau discuss partnering with an eye care provider and steps you and your patients can take to help proactively manage ocular events

Speak to an ELAHERE Rep

Have questions about ELAHERE? Contact a representative for help and updates.

Request a Rep

*Terms and conditions apply. Patients are eligible for co-pay assistance if enrolled in private commercial health insurance and are not covered by state or federal healthcare programs, and who meet the eligibility criteria. Patients will be enrolled for 12 months. There are no income requirements to participate in the program.
†Criteria include patients who are uninsured or have insurance that excludes coverage for ELAHERE (including patients on Medicare or Medicaid), residents of the United States or Puerto Rico, and patients who meet the financial eligibility requirements. Terms and conditions apply.
‡Providers are responsible for determining the appropriate coding and submission of accurate claims. AbbVie does not guarantee reimbursement or payment of claims.
AIBW=adjusted ideal body weight; EHR=electronic health record; FOLR1=folate receptor 1; FRα=folate receptor alpha; IHC=immunohistochemistry.

IMPORTANT SAFETY INFORMATION

WARNING: OCULAR TOXICITY

  • ELAHERE can cause severe ocular toxicities, including visual impairment, keratopathy, dry eye, photophobia, eye pain, and uveitis.
  • Conduct an ophthalmic exam including visual acuity and slit lamp exam prior to initiation of ELAHERE, every other cycle for the first 8 cycles, and as clinically indicated.
  • Administer prophylactic artificial tears and ophthalmic topical steroids.
  • Withhold ELAHERE for ocular toxicities until improvement and resume at the same or reduced dose.
  • Discontinue ELAHERE for Grade 4 ocular toxicities.

WARNINGS and PRECAUTIONS

Ocular Disorders

ELAHERE can cause severe ocular adverse reactions, including visual impairment, keratopathy (corneal disorders), dry eye, photophobia, eye pain, and uveitis.

Ocular adverse reactions occurred in 59% of patients with ovarian cancer treated with ELAHERE. Eleven percent (11%) of patients experienced Grade 3 ocular adverse reactions, including blurred vision, keratopathy (corneal disorders), dry eye, cataract, photophobia, and eye pain; two patients (0.3%) experienced Grade 4 events (keratopathy and cataract). The most common (≥5%) ocular adverse reactions were blurred vision (48%), keratopathy (36%), dry eye (27%), cataract (16%), photophobia (14%), and eye pain (10%).

The median time to onset for first ocular adverse reaction was 5.1 weeks (range: 0.1 to 68.6). Of the patients who experienced ocular events, 53% had complete resolution; 38% had partial improvement (defined as a decrease in severity by one or more grades from the worst grade at last follow up). Ocular adverse reactions led to permanent discontinuation of ELAHERE in 1% of patients.

Premedication and use of lubricating and ophthalmic topical steroid eye drops during treatment with ELAHERE are recommended. Advise patients to avoid use of contact lenses during treatment with ELAHERE unless directed by a healthcare provider.

Refer patients to an eye care professional for an ophthalmic exam including visual acuity and slit lamp exam prior to treatment initiation, every other cycle for the first 8 cycles, and as clinically indicated. Promptly refer patients to an eye care professional for any new or worsening ocular signs and symptoms.

Monitor for ocular toxicity and withhold, reduce, or permanently discontinue ELAHERE based on severity and persistence of ocular adverse reactions.

Pneumonitis

Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ELAHERE.

Pneumonitis occurred in 10% of patients treated with ELAHERE, including 1% with Grade 3 events and 1 patient (0.1%) with a Grade 4 event. One patient (0.1%) died due to respiratory failure in the setting of pneumonitis and lung metastases. One patient (0.1%) died due to respiratory failure of unknown etiology. Pneumonitis led to permanent discontinuation of ELAHERE in 3% of patients.

Monitor patients for pulmonary signs and symptoms of pneumonitis, which may include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams. Infectious, neoplastic, and other causes for such symptoms should be excluded through appropriate investigations. Withhold ELAHERE for patients who develop persistent or recurrent Grade 2 pneumonitis until symptoms resolve to ≤ Grade 1 and consider dose reduction. Permanently discontinue ELAHERE in all patients with Grade 3 or 4 pneumonitis. Patients who are asymptomatic may continue dosing of ELAHERE with close monitoring.

Peripheral Neuropathy (PN)

Peripheral neuropathy occurred in 36% of patients with ovarian cancer treated with ELAHERE across clinical trials; 3% of patients experienced Grade 3 peripheral neuropathy. Peripheral neuropathy adverse reactions included peripheral neuropathy (20%), peripheral sensory neuropathy (9%), paraesthesia (6%), neurotoxicity (3%), hypoaesthesia (1%), peripheral motor neuropathy (0.9%), polyneuropathy (0.3%), and peripheral sensorimotor neuropathy (0.1%). Monitor patients for signs and symptoms of neuropathy, such as paresthesia, tingling or a burning sensation, neuropathic pain, muscle weakness, or dysesthesia. For patients experiencing new or worsening PN, withhold dosage, dose reduce, or permanently discontinue ELAHERE based on the severity of PN.

Embryo-Fetal Toxicity

Based on its mechanism of action, ELAHERE can cause embryo-fetal harm when administered to a pregnant woman because it contains a genotoxic compound (DM4) and affects actively dividing cells.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ELAHERE and for 7 months after the last dose.

ADVERSE REACTIONS

The most common (≥20 %) adverse reactions, including lab abnormalities, were increased aspartate aminotransferase, fatigue, increased alanine aminotransferase, blurred vision, nausea, increased alkaline phosphatase, diarrhea, abdominal pain, keratopathy, peripheral neuropathy, musculoskeletal pain, decreased lymphocytes, decreased platelets, decreased magnesium, decreased hemoglobin, dry eye, constipation, decreased leukocytes, vomiting, decreased albumin, decreased appetite, and decreased neutrophils.

DRUG INTERACTIONS

DM4 is a CYP3A4 substrate. Closely monitor patients for adverse reactions with ELAHERE when used concomitantly with strong CYP3A4 inhibitors.

USE IN SPECIAL POPULATIONS

Lactation

Advise women not to breastfeed during treatment with ELAHERE and for 1 month after the last dose.

Hepatic Impairment

Avoid use of ELAHERE in patients with moderate or severe hepatic impairment (total bilirubin >1.5 ULN).

INDICATION

ELAHERE is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.

Please see Full Prescribing Information, including Boxed WARNING.

IMPORTANT SAFETY INFORMATION

WARNING: OCULAR TOXICITY

  • ELAHERE can cause severe ocular toxicities, including visual impairment, keratopathy, dry eye, photophobia, eye pain, and uveitis.
  • Conduct an ophthalmic exam including visual acuity and slit lamp exam prior to initiation of ELAHERE, every other cycle for the first 8 cycles, and as clinically indicated.
  • Administer prophylactic artificial tears and ophthalmic topical steroids.
  • Withhold ELAHERE for ocular toxicities until improvement and resume at the same or reduced dose.
  • Discontinue ELAHERE for Grade 4 ocular toxicities.

WARNINGS and PRECAUTIONS

Ocular Disorders

ELAHERE can cause severe ocular adverse reactions, including visual impairment, keratopathy (corneal disorders), dry eye, photophobia, eye pain, and uveitis.

Ocular adverse reactions occurred in 59% of patients with ovarian cancer treated with ELAHERE. Eleven percent (11%) of patients experienced Grade 3 ocular adverse reactions, including blurred vision, keratopathy (corneal disorders), dry eye, cataract, photophobia, and eye pain; two patients (0.3%) experienced Grade 4 events (keratopathy and cataract). The most common (≥5%) ocular adverse reactions were blurred vision (48%), keratopathy (36%), dry eye (27%), cataract (16%), photophobia (14%), and eye pain (10%).

The median time to onset for first ocular adverse reaction was 5.1 weeks (range: 0.1 to 68.6). Of the patients who experienced ocular events, 53% had complete resolution; 38% had partial improvement (defined as a decrease in severity by one or more grades from the worst grade at last follow up). Ocular adverse reactions led to permanent discontinuation of ELAHERE in 1% of patients.

Premedication and use of lubricating and ophthalmic topical steroid eye drops during treatment with ELAHERE are recommended. Advise patients to avoid use of contact lenses during treatment with ELAHERE unless directed by a healthcare provider.

Refer patients to an eye care professional for an ophthalmic exam including visual acuity and slit lamp exam prior to treatment initiation, every other cycle for the first 8 cycles, and as clinically indicated. Promptly refer patients to an eye care professional for any new or worsening ocular signs and symptoms.

Monitor for ocular toxicity and withhold, reduce, or permanently discontinue ELAHERE based on severity and persistence of ocular adverse reactions.

Pneumonitis

Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ELAHERE.

Pneumonitis occurred in 10% of patients treated with ELAHERE, including 1% with Grade 3 events and 1 patient (0.1%) with a Grade 4 event. One patient (0.1%) died due to respiratory failure in the setting of pneumonitis and lung metastases. One patient (0.1%) died due to respiratory failure of unknown etiology. Pneumonitis led to permanent discontinuation of ELAHERE in 3% of patients.

Monitor patients for pulmonary signs and symptoms of pneumonitis, which may include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams. Infectious, neoplastic, and other causes for such symptoms should be excluded through appropriate investigations. Withhold ELAHERE for patients who develop persistent or recurrent Grade 2 pneumonitis until symptoms resolve to ≤ Grade 1 and consider dose reduction. Permanently discontinue ELAHERE in all patients with Grade 3 or 4 pneumonitis. Patients who are asymptomatic may continue dosing of ELAHERE with close monitoring.

Peripheral Neuropathy (PN)

Peripheral neuropathy occurred in 36% of patients with ovarian cancer treated with ELAHERE across clinical trials; 3% of patients experienced Grade 3 peripheral neuropathy. Peripheral neuropathy adverse reactions included peripheral neuropathy (20%), peripheral sensory neuropathy (9%), paraesthesia (6%), neurotoxicity (3%), hypoaesthesia (1%), peripheral motor neuropathy (0.9%), polyneuropathy (0.3%), and peripheral sensorimotor neuropathy (0.1%). Monitor patients for signs and symptoms of neuropathy, such as paresthesia, tingling or a burning sensation, neuropathic pain, muscle weakness, or dysesthesia. For patients experiencing new or worsening PN, withhold dosage, dose reduce, or permanently discontinue ELAHERE based on the severity of PN.

Embryo-Fetal Toxicity

Based on its mechanism of action, ELAHERE can cause embryo-fetal harm when administered to a pregnant woman because it contains a genotoxic compound (DM4) and affects actively dividing cells.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ELAHERE and for 7 months after the last dose.

ADVERSE REACTIONS

The most common (≥20 %) adverse reactions, including lab abnormalities, were increased aspartate aminotransferase, fatigue, increased alanine aminotransferase, blurred vision, nausea, increased alkaline phosphatase, diarrhea, abdominal pain, keratopathy, peripheral neuropathy, musculoskeletal pain, decreased lymphocytes, decreased platelets, decreased magnesium, decreased hemoglobin, dry eye, constipation, decreased leukocytes, vomiting, decreased albumin, decreased appetite, and decreased neutrophils.

DRUG INTERACTIONS

DM4 is a CYP3A4 substrate. Closely monitor patients for adverse reactions with ELAHERE when used concomitantly with strong CYP3A4 inhibitors.

USE IN SPECIAL POPULATIONS

Lactation

Advise women not to breastfeed during treatment with ELAHERE and for 1 month after the last dose.

Hepatic Impairment

Avoid use of ELAHERE in patients with moderate or severe hepatic impairment (total bilirubin >1.5 ULN).

INDICATION

ELAHERE is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.

Please see Full Prescribing Information, including Boxed WARNING.

Call 1-833-ELAHERE1-833-ELAHERE for the ELAHERE Support Services Program

ORDER ELAHERE